Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major step toward an Alzheimer's vaccine

16.01.2013
A team of researchers from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease.

This major breakthrough, details of which are presented today in an early online edition of the Proceedings of the National Academy of Sciences (PNAS), opens the door to the development of a treatment for Alzheimer's disease and a vaccine to prevent the illness.

One of the main characteristics of Alzheimer's disease is the production in the brain of a toxic molecule known as amyloid beta. Microglial cells, the nervous system's defenders, are unable to eliminate this substance, which forms deposits called senile plaques.

The team led by Dr. Serge Rivest, professor at Université Laval's Faculty of Medicine and researcher at the CHU de Québec research center, identified a molecule that stimulates the activity of the brain's immune cells. The molecule, known as MPL (monophosphoryl lipid A), has been used extensively as a vaccine adjuvant by GSK for many years, and its safety is well established.

In mice with Alzheimer's symptoms, weekly injections of MPL over a twelve-week period eliminated up to 80% of senile plaques. In addition, tests measuring the mice's ability to learn new tasks showed significant improvement in cognitive function over the same period.

The researchers see two potential uses for MPL. It could be administered by intramuscular injection to people with Alzheimer's disease to slow the progression of the illness. It could also be incorporated into a vaccine designed to stimulate the production of antibodies against amyloid beta. "The vaccine could be given to people who already have the disease to stimulate their natural immunity," said Serge Rivest. "It could also be administered as a preventive measure to people with risk factors for Alzheimer's disease."

"When our team started working on Alzheimer's disease a decade ago, our goal was to develop better treatment for Alzheimer's patients," explained Professor Rivest. "With the discovery announced today, I think we're close to our objective."

In addition to Rivest, the study's co-authors are Jean-Philippe Michaud, Antoine Lampron, Peter Thériault, Paul Préfontaine, Mohammed Filali, and nine researchers from GlaxoSmithKline.

Source:

Jean-François Huppé
Media Relations
Université Laval
418-656-7785
Jean-Francois.Huppe@dc.ulaval.ca
Pascale St-Pierre
Media Relations
CHU de Québec
418-525-4387
Pascale.St-Pierre@chuq.qc.ca

Jean-François Huppé | EurekAlert!
Further information:
http://www.ulaval.ca

More articles from Health and Medicine:

nachricht Location of body fat can increase hypertension risk
02.09.2014 | American College of Cardiology

nachricht New tuberculosis blood test in children is reliable and highly specific
01.09.2014 | Swiss Tropical and Public Health Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

IT security in the digital society

27.08.2014 | Event News

Understanding the brain—neuroscientists meet in Göttingen

27.08.2014 | Event News

MEDICA EDUCATION CONFERENCE: Bessere Behandlung dank Biomarker

21.08.2014 | Event News

 
Latest News

A smart fluorescent antenna for Wi-Fi applications

02.09.2014 | Power and Electrical Engineering

Blowfly maggots provide physical evidence for forensic cases

02.09.2014 | Life Sciences

Single laser stops molecular tumbling motion instantly

02.09.2014 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>